Cardioprotective effect of fluvastatin XL

Between June 2004 and April 2008 the Dutch DECREASE III Study observed patients treated with Fluvastatin. The results show that Fluvastatin XL therapy can be associated with improved postoperative cardiac outcome in high-risk patients undergoing elective vascular surgery.

Annually, approximately 40 million people undergo noncardiac surgery in the European Union. Of these patients approximately 400,000 (1%) will suffer a perioperative myocardial infarction (PMI) while approximately 133,000 (0.3%) die because of cardiac complications. In particular in patients undergoing noncardiac vascular surgery the incidence of perioperative cardiac complications is high with cardiac mortality rates exceeding 2%. Indeed perioperative cardiac events are the major cause of adverse outcome in vascular surgery patients. 
The pathophysiology of a PMI is complex. While cardiac oxygen demand / supply mismatch in patients with coronary artery disease might be counteracted by appropriate beta-blocker use or coronary revascularization in these patients, coronary plaque instability leading to plaque rupture and thrombosis remains a significant problem. Recent retrospective studies suggested a potential beneficial role of statins in the prevention of PMI, in particular by “stabilizing” coronary plaques due to their pleiotropic, anti-inflammatory effects. Therefore the aim of the randomized, double blind, Dutch Echographic Cardiac Risk Evaluation Applying Stress Echo (DECREASE) III trial was to assess the cardioprotective effect of fluvastatin XL on top of beta-blocker therapy in vascular surgery patients.
Between June 2004 and April 2008 497 statin-naive patients scheduled for vascular surgery were included in the trial at Erasmus MC Rotterdam, the Netherlands. Patients were randomized to receive either placebo or fluvastatin extended release (Novartis, Basel, Switzerland) at a dose of 80 mg once daily. Treatment was started at the outpatient clinic on the day of randomization, median 37 days prior to the surgical procedure and was continued at least during the first 30 days after surgery. Inflammatory markers at baseline, including hs-CRP and IL-6 were assessed in patients allocated to fluvastatin or placebo. At hospital admission levels of hs-CRP and IL-6 were significantly lower in patients on fluvastatin (respectively 6.00 mg/L vs 4.66 mg/L, p=0.030 and 8.45 pg/ml vs 5.75 pg/ml, p=0.024). The primary analysis was intention-to-treat and involved all patients who were randomly assigned to either fluvastatin or placebo. Directly after surgery, study treatment was temporarily discontinued in 115 (23%) patients for a median duration of 2 days because of the inability to take the study drug orally. A total of 34 patients discontinued study medication because of laboratory abnormalities; 16 (3.2%) because of ALAT exceeding 3x upper limit of normal, 13 (2.6%) because of CK exceeding 10x upper limit of normal, and 5 (1.0%) because of a combination of elevated ALAT and CK.
Primary endpoint
Myocardial ischemia was detected in 74 (14.9%) patients within 30 days of the initial vascular surgical procedure. A total of 27/250 (10.9%) patients allocated to fluvastatin reached the primary endpoint compared to 47/247 (18.9%) patients allocated to placebo treatment (OR 0.53; 95% CI 0.32-0.88). Hence, the number needed to treat (NNT) to prevent one patient experiencing myocardial ischemia was 12.5 patients.
Secondary endpoint
A total of 18 (3.6%) patients died within 30 days after surgery of which 12 (2.4%) were attributable to cardiovascular causes. Additionally, 25 (5.0%) patients experienced a nonfatal myocardial infarction within 30 days after surgery. The combined endpoint of cardiovascular death and nonfatal myocardial infarction was reached in 37/497 (7.4%) patients. A total of 12/250 (4.8%) patients allocated to fluvastatin therapy reached the combined endpoint, compared to 25/247 (10.1%) allocated to placebo. Hence, fluvastatin therapy was associated with a 52% relative reduction in the incidence of cardiovascular death or MI (OR 0.48; 95% CI 0.24-0.95). The NNT for the composite endpoint of cardiovascular death or nonfatal MI is 18.9 patients.
Adverse events
The proportion of patients experiencing any adverse event was similar between the fluvastatin and placebo groups. The proportion of patients experiencing a CK rise > 10x the upper limit of normal was 4.1% in the fluvastatin group and 3.0% in the placebo group. The median peak CK level was 141 U/Lin patients on fluvastatin and 113 U/L in patients on placebo (p=0.24). The proportion of patients with significant increase in ALAT levels, ie > 3x times upper limit of normal, was 3.1% in the fluvastatin group and 5.2% in the placebo group. The median peak ALAT level was 23 U/L in patients on fluvastatin and 24U/L in patients on placebo.


Read all latest stories

Related articles


Article •

Hypertension worldwide

Countries vary widely in their capacity to manage hypertension, but globally the majority of diagnosed hypertensives is inadequately controlled. Not treated it can cause cardiovascular disease (CVD),…


Article • "Timely" study

Improved care after heart attack on AI-powered telemedicine platform

Coronary artery disease causes more than 1.8 million heart attacks each year in Europe. In most cases, rehabilitation helps the patients to return to their everyday life. But what happens once the…


News • Decision support system

Reducing high-risk drug combinations in the ICU

Fewer, but more relevant alerts in the ICU: Dutch researchers show how a computerized decision support system significantly reduces high-risk drug combinations in intensive care patients.

Related products

Subscribe to Newsletter